Omeros (NASDAQ:OMER) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Omeros (NASDAQ:OMER) from a sell rating to a hold rating in a report published on Thursday.

A number of other analysts have also recently commented on OMER. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th. RODMAN&RENSHAW upgraded Omeros to a “strong-buy” rating in a research report on Thursday, November 14th. D. Boral Capital reissued a “buy” rating and set a $36.00 price target on shares of Omeros in a research report on Thursday, February 20th. Needham & Company LLC restated a “hold” rating on shares of Omeros in a research note on Friday, January 17th. Finally, Rodman & Renshaw assumed coverage on shares of Omeros in a research note on Thursday, November 14th. They issued a “buy” rating and a $9.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $22.50.

Omeros Stock Down 1.9 %

NASDAQ OMER opened at $7.86 on Thursday. Omeros has a 52 week low of $2.61 and a 52 week high of $13.60. The firm has a market capitalization of $455.49 million, a price-to-earnings ratio of -3.40 and a beta of 2.03. The company has a fifty day moving average of $8.86 and a two-hundred day moving average of $7.12.

Institutional Trading of Omeros

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OMER. Nomura Holdings Inc. boosted its stake in shares of Omeros by 136.2% in the fourth quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company’s stock valued at $7,383,000 after purchasing an additional 430,932 shares during the period. Susquehanna Fundamental Investments LLC purchased a new position in Omeros in the 4th quarter valued at approximately $1,488,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Omeros in the fourth quarter worth $1,120,000. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Omeros during the fourth quarter worth $1,033,000. Finally, Ancora Advisors LLC raised its stake in shares of Omeros by 1,036.4% in the fourth quarter. Ancora Advisors LLC now owns 85,800 shares of the biopharmaceutical company’s stock valued at $848,000 after acquiring an additional 78,250 shares in the last quarter. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.